| Indacaterol | Salmeterol | Placebo | |
| Randomised | 333 (100.0) | 334 (100.0) | 335 (100.0) |
| Treated | 330 (99.1) | 333 (99.7) | 335 (100.0) |
| Completed | 289 (86.8) | 284 (85.0) | 265 (79.1) |
| Discontinued | 44 (13.2) | 50 (15.0) | 70 (20.9) |
| Primary reason for premature discontinuation | |||
| Adverse event(s) | 18 (5.4) | 16 (4.8) | 13 (3.9) |
| Protocol deviation | 9 (2.7) | 11 (3.3) | 13 (3.9) |
| Subject withdrew consent | 8 (2.4) | 12 (3.6) | 22 (6.6) |
| Abnormal lab value(s) | 2 (0.6) | 1 (0.3) | 2 (0.6) |
| Abnormal test procedure result(s) | 2 (0.6) | 1 (0.3) | 1 (0.3) |
| Lost to follow-up | 2 (0.6) | 5 (1.5) | 2 (0.6) |
| Unsatisfactory therapeutic effect | 1 (0.3) | 2 (0.6) | 15 (4.5) |
| Administrative problems | 1 (0.3) | 1 (0.3) | 0 |
| Death | 1 (0.3) | 0 | 3 (0.9) |
| Patient's inability to use the device | 0 | 1 (0.3) | 0 |
| Intention-to-treat population | 330 (99.1) | 333 (99.7) | 335 (100.0) |
| Safety population | 330 (99.1) | 333 (99.7) | 335 (100.0) |
Data are presented as n (%).